SCHEMBL3973373

SCHEMBL3973373

Clc1ccc2c(Cl)nc(-c3ccc(Br)cc3)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP1B1 Q16678 1/20 0.42
HDAC3 O15379 1/20 0.41
MTOR P42345 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
AHR P35869 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
POLB P06746 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
ADORA3 P0DMS8 2/20 0.39
HMOX1 P09601 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154965 0.90 NPC1 (0.46) HDAC3MTORHDAC1HDAC2HDAC6
SCHEMBL3972857 0.87 NPC1 (0.50) CYP1A1CYP1A2CYP1B1NPC1RAB9A
SCHEMBL3976375 0.84 HTT (0.54) CYP1A2NPC1RAB9AMEN1KMT2A
SCHEMBL402767 0.83 HTT (0.56) NPC1RAB9AMEN1KMT2AMAPK1
SCHEMBL30439291 0.83 HTT (0.56) NPC1RAB9AMEN1KMT2AMAPK1
SCHEMBL13312483 0.81 HTT (0.47) CYP1A1CYP1A2CYP1B1NPC1RAB9A
SCHEMBL5793174 0.80 CYP1B1 (0.64) CYP1A1CYP1A2CYP1B1NPC1RAB9A
SCHEMBL3977614 0.77 ABCG2 (0.66) MEN1KMT2APOLBAURKAMAPT
SCHEMBL3976324 0.76 SLC2A1 (0.56) NPC1RAB9AMEN1KMT2ANPSR1
SCHEMBL28129920 0.75 POLB (0.47) KMT2APOLBNR4A2ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 CYP1A1 1861/4885CYP1A2 1472/4885CYP1B1 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.